The current status of interferon‐α treatment in advanced renal cancer
The current status of interferon‐α treatment in advanced renal cancer
复制标题
干扰素-α治疗晚期肾癌的现状
DOI：
10.1046/j.1464-410x.2001.02140.x
复制
发表时间：
2001
影响因子：
4.5
通讯作者：
M. Gore
中科院分区：
文献类型：
--
作者：
J. Stebbing;M. Gore
肾细胞癌是第十大最常见的恶性肿瘤，发病率不断上升，估计每年在全世界造成9.5万人死亡。转移性疾病患者的预后很差，对化疗的反应率一直很低。早期病例对照研究和最近的随机数据表明，干扰素-a的使用以牺牲体质毒性为代价，与适度的生存获益相关。英国每年有5700例RCC，占所有恶性肿瘤的3%。局部肾细胞癌通常可以通过手术治愈。尽管发病时疾病明显局限，但20-30%的患者在根治性肾切除术后复发，通常伴有远处转移，另外20-30%的患者出现转移性疾病[3]。这些患者的5年生存率为4%，中位生存率为6个月。转移性肾细胞癌在其临床过程中通常是高度可变的，包括自发消退。我们面临的挑战是开发出更有效的治疗方法，特别是在门诊环境中尽可能以最小的副作用实现这一目标。转移性肾细胞癌最有希望的全身治疗是免疫（生物）治疗。20世纪60年代和70年代的实验报告表明，干扰素在广泛的实验室模型中具有抗肿瘤活性。它们的确切作用机制仍有争议，尽管它们似乎通过以下方式发挥作用：(1)刺激巨噬细胞的吞噬作用；（ii）上调MHC I类分子；（iii）对肿瘤细胞b[6]有直接的细胞毒性作用。早期的非随机研究结果表明，干扰素-a生物治疗在选定的患者中产生了< 15%的客观肿瘤反应率，转化为生存获益[5,7]。干扰素-a2b治疗转移性肾癌的疗效观察
RCC is the 10th commonest malignancy and has an increasing incidence, accounting for an estimated 95 000 deaths per year worldwide. The prognosis is poor for patients with metastatic disease and response rates to chemotherapy are consistently low. Early casecontrol studies and more recent randomized data suggest that the use of interferon-a is associated with a modest survival benefit at the expense of constitutional toxicity. There are <5700 cases of RCC per annum in the UK, comprising 3% of all malignancies [1]. Localized RCC can often be cured by surgery [2]. Despite apparently localized disease at presentation, 20–30% of patients relapse after radical nephrectomy, usually with distant metastases, and a further 20–30% of patients present with metastatic disease [3]. These patients have a 5-year survival of 4% and a median survival of 6 months [4]. Metastatic RCC is often highly variable in its clinical course, including spontaneous regressions [5]. The challenge has been to develop treatments with improved efficacy and in particular to achieve this with minimal side-effects if possible in the outpatient setting. The most promising systemic therapy for metastatic RCC is immuno-(biological) therapy. Experiments reported during the 1960s and 1970s showed that the interferons had antitumour activity in a wide range of laboratory models. Their exact mechanism of action remains in debate although they appear to exert their effect by: (i) stimulating phagocytosis by macrophages; (ii) up-regulating MHC class I molecules; and (iii) having a directly cytotoxic effect on tumour cells [6]. The results of early unrandomized studies suggested that biological therapy with interferon-a produced an objective tumour response rate of < 15% in selected patients that translated into a survival benefit [5,7]. The efficacy of interferon-a2b in the treatment of metastatic RCC
视黄酸和干扰素在肾癌细胞系中的相互作用。
DOI：
10.1089/10799900050151058
发表时间：
2000
期刊：
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
影响因子：
--
作者：
Nanus,DM;Geng,Y;Shen,R;Lai,HK;Pfeffer,SR;Pfeffer,LM
通讯作者：
Pfeffer,LM
影响因子：
45.3
作者：
Motzer, RJ;Murphy, BA;Mazumdar, M
通讯作者：
Mazumdar, M